TESAMORELIN

GHRH Analog • Growth Hormone & Metabolic Research Peptide

For Research Use Only

Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the body’s growth-hormone signaling pathway through activation of pituitary GHRH receptors.

Research has demonstrated that tesamorelin increases endogenous growth hormone (GH) signaling and subsequently increases circulating insulin-like growth factor-1 (IGF-1).

Unlike administration of growth hormone itself, tesamorelin acts upstream at the pituitary level, making it an important research tool for investigating the regulation of the GH/IGF-1 axis.

Research Areas

Tesamorelin has been studied in research involving:

• Growth hormone physiology
• GHRH receptor signaling
• GH/IGF-1 axis
• Pituitary function
• Visceral adipose tissue
• Adipose-tissue metabolism
• Lipid metabolism
• Body-composition physiology
• Hepatic fat metabolism
• Metabolic signaling
• Neuroendocrine physiology

Human randomized trials have demonstrated reductions in visceral adipose tissue (VAT) in adults with HIV-associated abdominal fat accumulation.

Mechanism Being Studied

Tesamorelin mimics endogenous GHRH, binding to GHRH receptors located on pituitary somatotroph cells.

The pathway can be summarized as:

Tesamorelin → GHRH Receptor → Pituitary GH Release → IGF-1 Signaling

Researchers use this pathway to investigate downstream effects involving:

• Growth hormone secretion
• IGF-1 production
• Lipid metabolism
• Adipocyte physiology
• Visceral adipose tissue
• Body composition
• Cellular growth and repair signaling
• Metabolic regulation

Clinical studies consistently demonstrate increases in IGF-1 during tesamorelin exposure.

Visceral Adipose Tissue Research

One of the most extensively researched aspects of tesamorelin is its relationship with visceral adipose tissue.

In a randomized controlled study of 404 adults with HIV and excess abdominal fat, visceral adipose tissue decreased approximately 10.9% after six months in the tesamorelin group compared with approximately 0.6% in the placebo group. Continued treatment produced a reduction of approximately 18% at 12 months.

Another randomized trial also reported reductions in visceral and liver fat in this specific population.

These findings should not be generalized to ordinary obesity or cosmetic fat loss.

Why Researchers Study Tesamorelin

Tesamorelin provides researchers with a way to investigate the GH/IGF-1 pathway while stimulating the body’s own pituitary GH secretion.

Areas of scientific interest include:

• Pulsatile growth-hormone physiology
• GHRH receptor activation
• IGF-1 signaling
• Visceral-fat metabolism
• Lipid mobilization
• Body-composition regulation
• Hepatic metabolism
• Neuroendocrine signaling

Research has also shown that visceral fat can reaccumulate after tesamorelin is discontinued, providing additional insight into the relationship between ongoing GHRH signaling and adipose-tissue physiology.

Product Features

✔ Premium Research Grade
✔ High-Purity Tesamorelin
✔ GHRH Analog Research Peptide
✔ Third-Party Tested (COA Available)
✔ Identity & Purity Verification
✔ Secure Professional Packaging
✔ Laboratory Research Only

Common Research Applications

Researchers may investigate tesamorelin in studies involving:

• GH/IGF-1 axis physiology
• Growth hormone secretion
• Pituitary signaling
• GHRH receptor biology
• Visceral adipose-tissue metabolism
• Lipid metabolism
• Body-composition research
• Hepatic metabolic pathways
• Endocrine physiology
• Neuroendocrine signaling

Storage

Store according to the product’s batch-specific stability documentation.

Protect lyophilized material from excessive heat, moisture, and direct sunlight.

Following preparation for laboratory experiments, use validated laboratory storage procedures and minimize unnecessary temperature cycling or repeated freeze-thaw exposure.

Important Research Distinction

FDA-approved tesamorelin exists as the prescription product EGRIFTA, including current formulations such as EGRIFTA WR. Its approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. FDA labeling specifically states that it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.

A Voltis research product should therefore not be represented as equivalent to an FDA-approved EGRIFTA product unless it actually holds the corresponding regulatory approval.

Disclaimer

For Research Use Only.

This Voltis product is intended exclusively for laboratory research and analytical purposes.

Tesamorelin is an active pharmaceutical ingredient associated with FDA-approved prescription products for a specific indication; however, a research-grade tesamorelin product is not itself an FDA-approved therapeutic product.

Not intended for human or veterinary use.

Why Choose Voltis Research Co.

At Voltis Research Co., quality begins with verification. Researchers deserve confidence that the compound identified on every vial accurately represents the material being investigated.

Qualifying batches undergo independent third-party analytical testing, with batch-specific Certificates of Analysis available to document identity and purity.

The Voltis Commitment

⚡ Research-Grade Quality
⚡ Independent Third-Party Testing
⚡ Batch-Specific Certificate of Analysis (COA)
⚡ High-Purity Research Peptides
⚡ Rigorous Quality Control
⚡ Secure Professional Packaging
⚡ Transparency, Consistency & Reliability

Powering Discovery Through Quality Research.